Clinical trials
Developmental and Epileptic Encephalopathy clinical trials
Below are recruiting developmental and epileptic encephalopathy clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06908226Enrolling by invitationPhase 3
LP352 for children and adults with DEE
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
Little Rock, ArkansasAges 2–66 - NCT07227857RecruitingPhase 1/Phase 2
Study of a new medicine for children with KCNT1-related epilepsy
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
Orange, CaliforniaAges 2–12 - NCT06380192Recruiting
Genetic Epilepsy and Development: A Natural History Study
This study looks at how a specific type of epilepsy with developmental challenges progresses over time. By reusing medical records, the researchers hope to learn more without extra hospital visits.
AmiensAges Any age - NCT06092346Recruiting
Understanding rare purine and pyrimidine metabolism disorders
This study aims to learn more about rare disorders of purine and pyrimidine metabolism (DPPM), which can affect the brain, immune system, kidneys, and muscles. Researchers will study people with these disorders, their family members, and healthy volunteers to better understand the condition over time.
Bethesda, MarylandAges 1 month–100 years - NCT06700811RecruitingPhase 1
Ketogenic diet to prevent infant seizures in genetic epilepsy
This trial tests whether starting a special high-fat diet (ketogenic diet) early can prevent epileptic spasms in babies with genetic epilepsy. It uses a specific formula called KetoVie and is for infants under 9 months old.
Boston, MassachusettsAges birth–9 months - NCT06855901Recruiting
Home EEG monitoring for rare epilepsy
This study tests using a small, home-based EEG device to monitor brain activity over several weeks in people with hard-to-control seizures, rare epilepsies, or developmental and epileptic encephalopathies. The goal is to see if this method can better track seizures and improve care.
Roma, ItalyAges 12 years+ - NCT06278428Recruiting
Epilepsy in Infants: Genes and Disease Course
This study looks at children with severe epilepsy that starts before age 2. It aims to understand how different gene changes affect the disease and how it progresses over time.
Ho Chi Minh CityAges Up to 1.9 years - NCT07531511Recruiting
Understanding SLC6A1 Genetic Disorder in Children
This study tracks how children with SLC6A1 genetic mutations develop over time. Researchers will collect information about seizures, development, and daily functioning to better understand the condition and help guide future treatments.
New York, New YorkAges Up to 17 years - NCT07413211Recruiting
Natural history study for genetic epilepsy and developmental delays
This study follows children and adults with genetic conditions that cause severe epilepsy and developmental delays (DEE), including those with MEF2C mutations. It aims to better understand these disorders and prepare for future clinical trials. You or your child can join in person (travel to NYC), virtually (online), or by filling out a registry.
New York, New YorkAges Any age - NCT07019922RecruitingPhase 3
A study of elsunersen for children with SCN2A-related epilepsy
This trial tests an experimental drug called elsunersen in children with a specific type of epilepsy caused by changes in the SCN2A gene. It aims to see if the drug can reduce seizures and be safe for children.
San Diego, CaliforniaAges 1 day–18 years - NCT06938542Enrolling by invitation
Palliative care needs for kids with rare diseases
This study asks children with rare diseases and their families about what kind of palliative care (comfort and support) they need. It aims to understand how to better help families through their child's illness.
Washington D.C., District of ColumbiaAges 1–99
Hear when a new Developmental and Epileptic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for developmental and epileptic encephalopathy?
- Yes. Clin2 currently lists 11 recruiting developmental and epileptic encephalopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a developmental and epileptic encephalopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a developmental and epileptic encephalopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.